Differences in α7 nicotinic acetylcholine receptor binding in motor symptomatic and asymptomatic MPTP-treated monkeys

Brain Research

Volumn 999, Issue 2, 2004, Pages 193-202

  Kulak, Jennifer M ^a   Schneider, Jay S ^a  

^a THOMAS JEFFERSON UNIVERSITY   (United States)

Author keywords

Autoradiography; Immunohistochemistry; Non human primate; Parkinson's disease; Bungarotoxin; 7 Nicotinic acetylcholine receptor

Indexed keywords

1,2,3,6 TETRAHYDRO 1 METHYL 4 PHENYLPYRIDINE; BUNGAROTOXIN; NICOTINIC RECEPTOR; ALPHA-BUNGAROTOXIN RECEPTOR; BUNGAROTOXIN RECEPTOR; GLIAL FIBRILLARY ACIDIC PROTEIN; RADIOACTIVE IODINE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; ASTROCYTE; BRAIN REGION; CAUDATE NUCLEUS; CINGULATE GYRUS; COGNITIVE DEFECT; CONTROLLED STUDY; DRUG RECEPTOR BINDING; HIPPOCAMPUS; IMMUNOHISTOCHEMISTRY; MONKEY; MOTOR ACTIVITY; MOTOR CORTEX; MOTOR DYSFUNCTION; MOTOR PERFORMANCE; NONHUMAN; PARKINSON DISEASE; PREFRONTAL CORTEX; PRIORITY JOURNAL; PROTEIN EXPRESSION; PUTAMEN; STAINING; SUBSTANTIA NIGRA; THALAMUS NUCLEUS; ADAPTATION; ANIMAL; BINDING COMPETITION; BRAIN; CHEMICALLY INDUCED DISORDER; DISEASE MODEL; DOSE RESPONSE; DRUG EFFECT; GLIOSIS; MACACA; METABOLISM; NEOSTRIATUM; PARKINSONISM; PATHOPHYSIOLOGY; PHYSIOLOGY; RADIOASSAY; UPREGULATION;

1-METHYL-4-PHENYL-1,2,3,6-TETRAHYDROPYRIDINE; ADAPTATION, PHYSIOLOGICAL; ANIMALS; BINDING, COMPETITIVE; BRAIN; BUNGAROTOXINS; COGNITION DISORDERS; DISEASE MODELS, ANIMAL; DOSE-RESPONSE RELATIONSHIP, DRUG; GLIAL FIBRILLARY ACIDIC PROTEIN; GLIOSIS; IMMUNOHISTOCHEMISTRY; IODINE RADIOISOTOPES; MACACA; NEOSTRIATUM; PARKINSONIAN DISORDERS; RADIOLIGAND ASSAY; RECEPTORS, NICOTINIC; UP-REGULATION;

EID: 0842324690     PISSN: 00068993     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.brainres.2003.10.062     Document Type: Article

References (46)

1. Cimino M., Marini P., Fornasari D., Cattabeni F., Clementi F. Distribution of nicotinic receptors in cynomolgus monkey brain and ganglia: localization of α3 subunit mRNA, α-bungarotoxin and nicotine binding sites. Neuroscience. 51:1992;77-86.
2. 125I]-α- bungarotoxin. J. Neurosci. 5:1985;1307-1315.
3. Cooper J.A., Sagar H.J., Jordan N., Harvey N.S., Sullivan E.V. Cognitive impairment in early, untreated Parkinson's disease and its relationship to motor disability. Brain. 114(Pt 5):1991;2095-2122.
4. Court J.A., Martin-Ruiz C., Graham A., Perry E. Nicotinic receptors in human brain: topography and pathology. J. Chem. Neuroanat. 20:2000;281-298.
5. Fabian-Fine R., Skehel P., Errington M.L., Davies H.A., Sher E., Stewart M.G., Fine A. Ultrastructural distribution of the alpha7 nicotinic acetylcholine receptor subunit in rat hippocampus. J. Neurosci. 21:2001;7993-8003.
6. Fagerstrom K.O., Pomerleau O., Giordani B., Stelson F. Nicotine may relieve symptoms of Parkinson's disease. Psychopharmacology (Berl). 116:1994;117-119.
7. Flowers K.A., Robertson C. The effect of Parkinson's disease on the ability to maintain a mental set. J. Neurol. Neurosurg. Psychiatry. 48:1985;517-529.
8. Freedman M., Oscar-Berman M. Selective delayed response deficits in Parkinson's and Alzheimer's disease. Arch. Neurol. 43:1986;886-890.
9. Gaspar P., Duyckaerts C., Alvarez C., Javoy-Agid F., Berger B. Alterations of dopaminergic and noradrenergic innervations in motor cortex in Parkinson's disease. Ann. Neurol. 30:1991;365-374.
10. Gotti C., Fornasari D., Clementi F. Human neuronal nicotinic receptors. Prog. Neurobiol. 53:1997;199-237.
11. 3H] dopamine release from synaptosomes prepared from mouse striatum. J. Neurochem. 59:1992;848-856.
12. Graham A., Court J.A., Martin-Ruiz C.M., Jaros E., Perry R., Volsen S.G., Bose S., Evans N., Ince P., Kuryatov A., Lindstrom J., Gotti C., Perry E.K. Immunohistochemical localisation of nicotinic acetylcholine receptor subunits in human cerebellum. Neuroscience. 113:2002;493-507.
13. Grottick A.J., Higgins G.A. Effect of subtype selective nicotinic compounds on attention as assessed by the five-choice serial reaction time task. Behav. Brain Res. 117:2000;197-208.
14. Grottick A.J., Trube G., Corrigall W.A., Huwyler J., Malherbe P., Wyler R., Higgins G.A. Evidence that nicotinic alpha(7) receptors are not involved in the hyperlocomotor and rewarding effects of nicotine. J. Pharmacol. Exp. Ther. 294:2000;1112-1119.
15. Ishikawa A., Miyatake T. Effects of smoking in patients with early-onset Parkinson's disease. J. Neurol. Sci. 117:1993;28-32.
16. 3H]dopamine release in rat striatal slices via glutamate release. Mol. Pharmacol. 58:2000;312-318.
17. Kulak J.M., Nguyen T.A., Yoshikami D., Olivera B.M., McIntosh J.M. α-Conotoxin MII blocks nicotine-stimulated dopamine release from rat striatal synaptosomes. J. Neurosci. 17:1997;5263-5270.
18. Kulak J.M., McIntosh J.M., Quik M. Loss of nicotinic receptors in monkey striatum after 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine treatment is due to a decline in α-conotoxin MII sites. Mol. Pharmacol. 61:2002;230-238.
19. Kulak J.M., Musachio J.L., McIntosh J.M., Quik M. Declines in different beta2* nicotinic receptor populations in monkey striatum after nigrostriatal damage. J. Pharmacol. Exp. Ther. 303:2002;633-639.
20. Lees A.J., Smith E. Cognitive deficits in the early stages of Parkinson's disease. Brain. 106(Pt 2):1983;257-270.
21. Levin E.D., Simon B.B. Nicotinic acetylcholine involvement in cognitive function in animals. Psychopharmacology. 138:1998;217-230.
22. Levin B.E., Llabre M.M., Weiner W.J. Cognitive impairments associated with early Parkinson's disease. Neurology. 39:1989;557-561.
23. Levin E.D., Bettegowda C., Blosser J., Gordon J. AR-R17779, and alpha7 nicotinic agonist, improves learning and memory in rats. Behav. Pharmacol. 10:1999;675-680.
24. Levin E.D., Bradley A., Addy N., Sigurani N. Hippocampal alpha 7 and alpha 4 beta 2 nicotinic receptors and working memory. Neuroscience. 109:2002;757-765.
25. Marks M.J., Stitzel J.A., Romm E., Wehner J.M., Collins A.C. Nicotinic binding sites in rat and mouse brain: comparison of acetylcholine, nicotine, and alpha-bungarotoxin. Mol. Pharmacol. 30:1986;427-436.
26. Martin-Ruiz C., Lawrence S., Piggott M., Kuryatov A., Lindstrom J., Gotti C., Cookson M.R., Perry R.H., Jaros E., Perry E.K., Court J.A. Nicotinic receptors in the putamen of patients with dementia with Lewy bodies and Parkinson's disease: relation to changes in alpha-synuclein expression. Neurosci. Lett. 335:2002;134-138.
27. 3H]epibatidine. Brain Res. 801:1998;143-149.
28. McGehee D.S. Molecular diversity of neuronal nicotinic acetylcholine receptors. Ann. N. Y. Acad. Sci. 868:1999;565-577.
29. Moll H. The treatment of post-encephalitic parkinsonism by nicotine. Br. Med. J. 1926;1079-1081.
30. Morecraft R.J., Van Hoesen G.W. Frontal granular cortex input to the cingulate (M3), supplementary (M2) and primary (M1) motor cortices in the rhesus monkey. J. Comp. Neurol. 337:1993;669-689.
31. Owen A.M., James M., Leigh P.N., Summers B.A., Marsden C.D., Quinn N.P., Lange K.W., Robbins T.W. Fronto-striatal cognitive deficits at different stages of Parkinson's disease. Brain. 115(Pt 6):1992;1727-1751.
32. Perry E., Martin-Ruiz C., Lee M., Griffiths M., Johnson M., Piggott M., Haroutunian V., Buxbaum J.D., Nasland J., Davis K., Gotti C., Clementi F., Tzartos S., Cohen O., Soreq H., Jaros E., Perry R., Ballard C., McKeith I., Court J. Nicotinic receptor subtypes in human brain ageing, Alzheimer and Lewy body diseases. Eur. J. Pharmacol. 393:2000;215-222.
33. Pillon B., Dubois B., Bonnet A.M., Esteguy M., Guimaraes J., Vigouret J.M., Lhermitte F., Agid Y. Cognitive slowing in Parkinson's disease fails to respond to levodopa treatment: the 15-objects test. Neurology. 39:1989;762-768.
34. Quik M., Polonskaya Y., McIntosh J.M., Kulak J.M. Differential nicotinic receptor expression in monkey basal ganglia: effects of nigrostriatal damage. Neuroscience. 112:2002;619-630.
35. 3H]dopamine release from striatal synaptosomes: pharmacological characterization. J. Neurochem. 54:1990;937-945.
36. Rusted J.M., Newhouse P.A., Levin E.D. Nicotinic treatment for degenerative neuropsychiatric disorders such as Alzheimer's disease and Parkinson's disease. (In Process Citation) Behav. Brain Res. 113:2000;121-129.
37. Schneider J.S., Pope-Coleman A., Van Velson M., Menzaghi F., Lloyd G.K. Effects of SIB-1508Y, a novel neuronal nicotinic acetylcholine receptor agonist, on motor behavior in parkinsonian monkeys. Mov. Disord. 13:1998;637-642.
38. Schneider J.S., Van Velson M., Menzaghi F., Lloyd G.K. Effects of the nicotinic acetylcholine receptor agonist SIB-1508Y on object retrieval performance in MPTP-treated monkeys: comparison with levodopa treatment. Ann. Neurol. 43:1998;311-317.
39. Schneider J.S., Tinker J.P., Van Velson M., Menzaghi F., Lloyd G.K. Nicotinic acetylcholine receptor agonist SIB-1508Y improves cognitive functioning in chronic low-dose MPTP-treated monkeys. J. Pharmacol. Exp. Ther. 290:1999;731-739.
40. Sharma G., Vijayaraghavan S. Nicotinic cholinergic signaling in hippocampal astrocytes involves calcium-induced calcium release from intracellular stores. Proc. Natl. Acad Sci. U. S. A. 98:2001;4148-4153.
41. Sharpe M.H. Distractibility in early Parkinson's disease. Cortex. 26:1990;239-246.
42. Sharpe M.H. Auditory attention in early Parkinson's disease: an impairment in focused attention. Neuropsychologia. 30:1992;101-106.
43. Swanson L.W., Simmons D.M., Whiting P.J., Lindstrom J. Immunohistochemical localization of neuronal nicotinic receptors in the rodent central nervous system. J. Neurosci. 7:1987;3334-3342.
44. Wade T.V., Schneider J.S. Expression of striatal preprotachykinin mRNA in symptomatic and asymptomatic 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine- exposed monkeys is related to parkinsonian motor signs. J. Neurosci. 21:2001;4901-4907.
45. Williams S.M., Goldman-Rakic P.S. Widespread origin of the primate mesofrontal dopamine system. Cereb. Cortex. 8:1998;321-345.
46. Wonnacott S. Presynaptic nicotinic ACh receptors. Trends Neurosci. 20:1997;92-98.